203 related articles for article (PubMed ID: 15156183)
1. ETO interacting proteins.
Hug BA; Lazar MA
Oncogene; 2004 May; 23(24):4270-4. PubMed ID: 15156183
[TBL] [Abstract][Full Text] [Related]
2. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
Ibañez V; Sharma A; Buonamici S; Verma A; Kalakonda S; Wang J; Kadkol S; Saunthararajah Y
Cancer Res; 2004 Jul; 64(13):4547-54. PubMed ID: 15231665
[TBL] [Abstract][Full Text] [Related]
3. Domains involved in ETO and human N-CoR interaction and ETO transcription repression.
Wang J; Wang M; Liu JM
Leuk Res; 2004 Apr; 28(4):409-14. PubMed ID: 15109542
[TBL] [Abstract][Full Text] [Related]
4. ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
Amann JM; Nip J; Strom DK; Lutterbach B; Harada H; Lenny N; Downing JR; Meyers S; Hiebert SW
Mol Cell Biol; 2001 Oct; 21(19):6470-83. PubMed ID: 11533236
[TBL] [Abstract][Full Text] [Related]
5. Targeting fusion protein/corepressor contact restores differentiation response in leukemia cells.
Racanicchi S; Maccherani C; Liberatore C; Billi M; Gelmetti V; Panigada M; Rizzo G; Nervi C; Grignani F
EMBO J; 2005 Mar; 24(6):1232-42. PubMed ID: 15729358
[TBL] [Abstract][Full Text] [Related]
6. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
7. The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignancies.
Hoogeveen AT; Rossetti S; Stoyanova V; Schonkeren J; Fenaroli A; Schiaffonati L; van Unen L; Sacchi N
Oncogene; 2002 Sep; 21(43):6703-12. PubMed ID: 12242670
[TBL] [Abstract][Full Text] [Related]
8. Retinoid receptors in health and disease: co-regulators and the chromatin connection.
Minucci S; Pelicci PG
Semin Cell Dev Biol; 1999 Apr; 10(2):215-25. PubMed ID: 10441075
[TBL] [Abstract][Full Text] [Related]
9. Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism.
McGhee L; Bryan J; Elliott L; Grimes HL; Kazanjian A; Davis JN; Meyers S
J Cell Biochem; 2003 Aug; 89(5):1005-18. PubMed ID: 12874834
[TBL] [Abstract][Full Text] [Related]
10. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
Gelmetti V; Zhang J; Fanelli M; Minucci S; Pelicci PG; Lazar MA
Mol Cell Biol; 1998 Dec; 18(12):7185-91. PubMed ID: 9819405
[TBL] [Abstract][Full Text] [Related]
11. Cooperative function of Aml1-ETO corepressor recruitment domains in the expansion of primary bone marrow cells.
Hug BA; Lee SY; Kinsler EL; Zhang J; Lazar MA
Cancer Res; 2002 May; 62(10):2906-12. PubMed ID: 12019171
[TBL] [Abstract][Full Text] [Related]
12. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
[TBL] [Abstract][Full Text] [Related]
14. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
Wang J; Hoshino T; Redner RL; Kajigaya S; Liu JM
Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10860-5. PubMed ID: 9724795
[TBL] [Abstract][Full Text] [Related]
15. Coactivator and corepressor complexes in nuclear receptor function.
Xu L; Glass CK; Rosenfeld MG
Curr Opin Genet Dev; 1999 Apr; 9(2):140-7. PubMed ID: 10322133
[TBL] [Abstract][Full Text] [Related]
16. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
17. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.
Minucci S; Maccarana M; Cioce M; De Luca P; Gelmetti V; Segalla S; Di Croce L; Giavara S; Matteucci C; Gobbi A; Bianchini A; Colombo E; Schiavoni I; Badaracco G; Hu X; Lazar MA; Landsberger N; Nervi C; Pelicci PG
Mol Cell; 2000 May; 5(5):811-20. PubMed ID: 10882117
[TBL] [Abstract][Full Text] [Related]
18. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
19. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
[TBL] [Abstract][Full Text] [Related]
20. ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes.
Salat D; Liefke R; Wiedenmann J; Borggrefe T; Oswald F
Mol Cell Biol; 2008 May; 28(10):3502-12. PubMed ID: 18332109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
